{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T01:10:06Z","timestamp":1790298606427,"version":"4.1.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,10,17]],"date-time":"2019-10-17T00:00:00Z","timestamp":1571270400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,10,17]],"date-time":"2019-10-17T00:00:00Z","timestamp":1571270400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Catharina Research Fund"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1007\/s11523-019-00681-1","type":"journal-article","created":{"date-parts":[[2019,10,17]],"date-time":"2019-10-17T08:06:26Z","timestamp":1571299586000},"page":"699-705","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Addition of Bevacizumab to First-Line Palliative Chemotherapy in Patients with Metastatic Small Bowel Adenocarcinoma: A Population-Based Study"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0305-391X","authenticated-orcid":false,"given":"Laura M.","family":"Legu\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felice N.","family":"van Erning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nienke","family":"Bernards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valery E. P. P.","family":"Lemmens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignace H. J. T.","family":"de Hingh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geert-Jan","family":"Creemers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,17]]},"reference":[{"issue":"9","key":"681_CR1","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1093\/annonc\/mdq038","volume":"21","author":"A Zaanan","year":"2010","unstructured":"Zaanan A, Costes L, Gauthier M, et al. Chemotherapy of advanced small-bowel adenocarcinoma: a multicenter AGEO study. Ann Oncol. 2010;21(9):1786\u201393.","journal-title":"Ann Oncol"},{"issue":"2","key":"681_CR2","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.dld.2013.04.013","volume":"46","author":"T Aparicio","year":"2014","unstructured":"Aparicio T, Zaanan A, Svrcek M, et al. Small bowel adenocarcinoma: epidemiology, risk factors, diagnosis and treatment. Dig Liver Dis. 2014;46(2):97\u2013104.","journal-title":"Dig Liver Dis."},{"issue":"1","key":"681_CR3","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1097\/SLA.0b013e31818e4641","volume":"249","author":"KY Bilimoria","year":"2009","unstructured":"Bilimoria KY, Bentrem DJ, Wayne JD, Ko CY, Bennett CL, Talamonti MS. Small bowel cancer in the United States: changes in epidemiology, treatment, and survival over the last 20 years. Ann Surg. 2009;249(1):63\u201371.","journal-title":"Ann Surg"},{"issue":"3","key":"681_CR4","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1002\/cncr.20404","volume":"101","author":"BS Dabaja","year":"2004","unstructured":"Dabaja BS, Suki D, Pro B, Bonnen M, Ajani J. Adenocarcinoma of the small bowel: presentation, prognostic factors, and outcome of 217 patients. Cancer. 2004;101(3):518\u201326.","journal-title":"Cancer"},{"issue":"9\u201310","key":"681_CR5","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1080\/0284186X.2016.1182211","volume":"55","author":"LM Legue","year":"2016","unstructured":"Legue LM, Bernards N, Gerritse SL, et al. Trends in incidence, treatment and survival of small bowel adenocarcinomas between 1999 and 2013: a population-based study in The Netherlands. Acta Oncol. 2016;55(9\u201310):1183\u20139.","journal-title":"Acta Oncol"},{"issue":"8","key":"681_CR6","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1002\/cncr.23822","volume":"113","author":"MJ Overman","year":"2008","unstructured":"Overman MJ, Kopetz S, Wen S, et al. Chemotherapy with 5-fluorouracil and a platinum compound improves outcomes in metastatic small bowel adenocarcinoma. Cancer. 2008;113(8):2038\u201345.","journal-title":"Cancer"},{"issue":"16","key":"681_CR7","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1200\/JCO.2008.19.7145","volume":"27","author":"MJ Overman","year":"2009","unstructured":"Overman MJ, Varadhachary GR, Kopetz S, et al. Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater. J Clin Oncol. 2009;27(16):2598\u2013603.","journal-title":"J Clin Oncol"},{"issue":"9","key":"681_CR8","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1634\/theoncologist.2012-0079","volume":"17","author":"T Tsushima","year":"2012","unstructured":"Tsushima T, Taguri M, Honma Y, et al. Multicenter retrospective study of 132 patients with unresectable small bowel adenocarcinoma treated with chemotherapy. Oncologist. 2012;17(9):1163\u201370.","journal-title":"Oncologist."},{"issue":"5","key":"681_CR9","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1097\/CAD.0b013e328350dd0d","volume":"23","author":"XJ Xiang","year":"2012","unstructured":"Xiang XJ, Liu YW, Zhang L, et al. A phase II study of modified FOLFOX as first-line chemotherapy in advanced small bowel adenocarcinoma. Anticancer Drugs. 2012;23(5):561\u20136.","journal-title":"Anticancer Drugs"},{"issue":"4","key":"681_CR10","first-page":"689","volume":"16","author":"L Zhang","year":"2011","unstructured":"Zhang L, Wang LY, Deng YM, et al. Efficacy of the FOLFOX\/CAPOX regimen for advanced small bowel adenocarcinoma: a three-center study from China. J Buon. 2011;16(4):689\u201396.","journal-title":"J Buon."},{"issue":"12","key":"681_CR11","doi-asserted-by":"publisher","first-page":"3057","DOI":"10.1038\/bjc.2013.677","volume":"109","author":"T Aparicio","year":"2013","unstructured":"Aparicio T, Svrcek M, Zaanan A, et al. Small bowel adenocarcinoma phenotyping, a clinicobiological prognostic study. Br J Cancer. 2013;109(12):3057\u201366.","journal-title":"Br J Cancer"},{"issue":"10","key":"681_CR12","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1038\/bjc.2016.309","volume":"115","author":"TW Kim","year":"2016","unstructured":"Kim TW, Elme A, Kusic Z, et al. A phase 3 trial evaluating panitumumab plus best supportive care vs best supportive care in chemorefractory wild-type KRAS or RAS metastatic colorectal cancer. Br J Cancer. 2016;115(10):1206\u201314.","journal-title":"Br J Cancer"},{"issue":"12","key":"681_CR13","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1200\/JCO.2007.14.9930","volume":"26","author":"LB Saltz","year":"2008","unstructured":"Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26(12):2013\u20139.","journal-title":"J Clin Oncol"},{"issue":"13","key":"681_CR14","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1200\/JCO.2006.08.1620","volume":"25","author":"E Van Cutsem","year":"2007","unstructured":"Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol. 2007;25(13):1658\u201364.","journal-title":"J Clin Oncol"},{"issue":"31","key":"681_CR15","doi-asserted-by":"publisher","first-page":"4706","DOI":"10.1200\/JCO.2009.27.6055","volume":"28","author":"M Peeters","year":"2010","unstructured":"Peeters M, Price TJ, Cervantes A, et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol. 2010;28(31):4706\u201313.","journal-title":"J Clin Oncol"},{"issue":"23","key":"681_CR16","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa032691","volume":"350","author":"H Hurwitz","year":"2004","unstructured":"Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350(23):2335\u201342.","journal-title":"N Engl J Med"},{"issue":"16","key":"681_CR17","doi-asserted-by":"publisher","first-page":"3697","DOI":"10.1200\/JCO.2005.05.112","volume":"23","author":"FF Kabbinavar","year":"2005","unstructured":"Kabbinavar FF, Schulz J, McCleod M, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol. 2005;23(16):3697\u2013705.","journal-title":"J Clin Oncol"},{"issue":"15","key":"681_CR18","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1200\/JCO.2010.33.5091","volume":"29","author":"E Van Cutsem","year":"2011","unstructured":"Van Cutsem E, Kohne CH, Lang I, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol. 2011;29(15):2011\u20139.","journal-title":"J Clin Oncol"},{"issue":"6","key":"681_CR19","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1002\/cncr.30445","volume":"123","author":"P Gulhati","year":"2017","unstructured":"Gulhati P, Raghav K, Shroff RT, et al. Bevacizumab combined with capecitabine and oxaliplatin in patients with advanced adenocarcinoma of the small bowel or ampulla of vater: A single-center, open-label, phase 2 study. Cancer. 2017;123(6):1011\u20137.","journal-title":"Cancer"},{"issue":"2","key":"681_CR20","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.3892\/ol.2017.6290","volume":"14","author":"M Hirao","year":"2017","unstructured":"Hirao M, Komori M, Nishida T, et al. Clinical use of molecular targeted agents for primary small bowel adenocarcinoma: a multicenter retrospective cohort study by the Osaka Gut Forum. Oncol Lett. 2017;14(2):1628\u201336.","journal-title":"Oncol Lett."},{"issue":"2","key":"681_CR21","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s00280-017-3371-0","volume":"80","author":"K Takayoshi","year":"2017","unstructured":"Takayoshi K, Kusaba H, Uenomachi M, et al. Suggestion of added value by bevacizumab to chemotherapy in patients with unresectable or recurrent small bowel cancer. Cancer Chemother Pharmacol. 2017;80(2):333\u201342.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"681_CR22","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.clcc.2016.04.013","volume":"16","author":"D Aydin","year":"2017","unstructured":"Aydin D, Sendur MA, Kefeli U, et al. Evaluation of bevacizumab in advanced small bowel adenocarcinoma. Clin Colorectal Cancer. 2017;16(1):78\u201383.","journal-title":"Clin Colorectal Cancer."},{"issue":"3","key":"681_CR23","doi-asserted-by":"publisher","first-page":"e9672","DOI":"10.1097\/MD.0000000000009672","volume":"97","author":"R Falcone","year":"2018","unstructured":"Falcone R, Roberto M, Filetti M, Anselmi E, Marchetti P. Anti epidermal growth factor receptor therapy in small bowel adenocarcinoma: case report and literature review. Medicine (Baltimore). 2018;97(3):e9672.","journal-title":"Medicine (Baltimore)."},{"issue":"3","key":"681_CR24","doi-asserted-by":"publisher","first-page":"277-e26","DOI":"10.1634\/theoncologist.2017-0568","volume":"23","author":"P Gulhati","year":"2018","unstructured":"Gulhati P, Raghav K, Shroff R, et al. Phase II study of panitumumab in RAS wild-type metastatic adenocarcinoma of small bowel or ampulla of vater. Oncologist. 2018;23(3):277-e26.","journal-title":"Oncologist."},{"issue":"18","key":"681_CR25","doi-asserted-by":"publisher","first-page":"3494","DOI":"10.1002\/cncr.30766","volume":"123","author":"RR McWilliams","year":"2017","unstructured":"McWilliams RR, Foster NR, Mahoney MR, et al. North Central Cancer Treatment Group N0543 (Alliance): a phase 2 trial of pharmacogenetic-based dosing of irinotecan, oxaliplatin, and capecitabine as first-line therapy for patients with advanced small bowel adenocarcinoma. Cancer. 2017;123(18):3494\u2013501.","journal-title":"Cancer"},{"issue":"1","key":"681_CR26","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/sj.bjc.6605449","volume":"102","author":"MJ Overman","year":"2010","unstructured":"Overman MJ, Pozadzides J, Kopetz S, et al. Immunophenotype and molecular characterisation of adenocarcinoma of the small intestine. Br J Cancer. 2010;102(1):144\u201350.","journal-title":"Br J Cancer"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-019-00681-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11523-019-00681-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-019-00681-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T23:18:06Z","timestamp":1602803886000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11523-019-00681-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,17]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["681"],"URL":"https:\/\/doi.org\/10.1007\/s11523-019-00681-1","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,17]]},"assertion":[{"value":"17 October 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This work was financially supported by a grant from the Catharina Research Fund, which was used for additional data collection, and had no involvement in relation to the presented outcomes.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"LL, FvE, NB, VL, IdH and GC declare that they have no conflicts of interest that might be relevant to the contents of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"According to the Central Committee on Research involving Human Subjects (CCMO), this type of study does not require approval from an ethics committee.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}